clinical trial
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
Day One Biopharmaceuticals Begins Combination Portion of Trial in MAPK-Altered Tumors
Following on a monotherapy study initiated last year, the new study will combine two of Day One's investigational compounds: a Raf kinase inhibitor and a MEK inhibitor.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
Aileron Begins Treating p53-Mutated Breast Cancer Patients in Study of Chemo-Protective Drug
The trial will explore whether ALRN-6924 prevents toxicity in patients receiving neoadjuvant chemotherapy treatment.